Literature DB >> 8097804

Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk.

P K Jha1, V Beral, J Peto, S Hack, C Hermon, J Deacon, D Mant, C Chilvers, M P Vessey, M C Pike.   

Abstract

Human papillomaviruses (HPVs) play an important part in the development of cervical cancer, but the role of other infectious agents, such as herpes simplex virus (HSV), is not clear. We assayed serum samples collected from 219 women with cervical cancer and from 387 controls for antibody to infectious agents. HPV 16-E7 and/or HPV 18-E7 antibodies were significantly related to cervical cancer risk (RR 1.9, 95% CI 1.2-3.2). Antibodies to HSV types 1 and 2, Chlamydia trachomatis, and to multiple infectious agents were associated with cervical cancer when seroprevalence rates in all cases and controls were compared, but when HPV-seropositive cases and controls were compared these associations were weaker and non-significant. This finding suggests that past infections with sexually transmitted infections other than HPV may be surrogate markers of exposure to HPV, and of no separate aetiological significance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097804     DOI: 10.1016/0140-6736(93)93128-n

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Sexually transmitted infections and cervical neoplasia.

Authors:  G la Ruche; H Faye-Ketté; H S Bankolé; F Dabis
Journal:  Int J STD AIDS       Date:  2000-01       Impact factor: 1.359

Review 2.  Recent trends in the epidemiology of sexually transmitted infections in the European Union.

Authors:  K A Fenton; C M Lowndes
Journal:  Sex Transm Infect       Date:  2004-08       Impact factor: 3.519

3.  Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.

Authors:  V Verhoeven; M Baay; J Weyler; D Avonts; F Lardon; P Van Royen; J B Vermorken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

4.  T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; A Judd; A B Moscicki; A J Canchola; J F Hilton; J M Palefsky
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.

Authors:  Sanjana Balachandra; Samuel B Kusin; Rebecca Lee; James-Michael Blackwell; Jasmin A Tiro; Lindsay G Cowell; Cheng-Ming Chiang; Shwu-Yuan Wu; Sanskriti Varma; Erika L Rivera; Helen G Mayo; Lianghao Ding; Baran D Sumer; Jayanthi S Lea; Aditya Bagrodia; Linda M Farkas; Richard Wang; Carole Fakhry; Kristina R Dahlstrom; Erich M Sturgis; Andrew T Day
Journal:  Cancer       Date:  2020-12-03       Impact factor: 6.860

Review 6.  Cervical cancer: is herpes simplex virus type II a cofactor?

Authors:  C Jones
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

8.  Vagina dentata revisited: gender and asymptomatic shedding of genital herpes.

Authors:  K L Pliskin
Journal:  Cult Med Psychiatry       Date:  1995-12

9.  Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease.

Authors:  J E Macgregor; M K Campbell; E M Mann; K Y Swanson
Journal:  BMJ       Date:  1994-05-28

10.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.